<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780519</url>
  </required_header>
  <id_info>
    <org_study_id>12-006469</org_study_id>
    <nct_id>NCT01780519</nct_id>
  </id_info>
  <brief_title>The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms</brief_title>
  <official_title>The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' goal is to determine if certain tests of memory and attention, performed
      while sleepiness is induced by a single dose of lorazepam, can predict whether or not an
      individual is at risk for developing Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>AVLT Long term memory score</measure>
    <time_frame>baseline to 5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The AVLT (Rey Auditory Verbal Learning Test),  a verbal memory test, is a 15-word list presented over 5 learning trials. After each presentation, the subject immediately repeats as many words as possible, then does so again after 30 minutes, which is the &quot;long-term memory&quot; score. &quot;Percent recall&quot; is long-term memory divided by learning trial 5. The &quot;learning over trials&quot; score reflects the increment in words repeated over the 5 successive learning trials. Six equivalent alternate forms of the AVLT will be randomly assigned to each subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Groton Maze Learning Test (GMLT) score</measure>
    <time_frame>baseline to 5 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The GMLT assesses visuospatial working memory, error monitoring, information processing speed, and short-term delayed recall for a complex hidden maze. Subjects are familiarized with the task during two untimed practice tests, and once the tester is confident that the subject understands the rules and can move easily around the grid, the timed test is administered. In each of the 5 successive trials of the GMLT exam, the subject is asked to learn to navigate his or her way around a 28-step maze that is hidden beneath a 10 x 10 grid of squares on the computer touch screen.  For each trial, the time to completion, number of correct moves, number of wrong moves, and the number of perseverative errors are recorded.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>L/VL APOE e3/e4 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L/S APOE e3/e4 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>long and short poly - T variants of TOMM40 and APOE e3/e4 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VL/VL  APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Very long poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/S APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>short poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <description>single dose of 1 mg lorazepam</description>
    <arm_group_label>L/VL APOE e3/e4 carrier</arm_group_label>
    <arm_group_label>L/S APOE e3/e4 carrier</arm_group_label>
    <arm_group_label>S/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_label>VL/VL  APOE e3/e3 carrier</arm_group_label>
    <arm_group_label>S/S APOE e3/e3 carrier</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  MMSE score of 28-30

          -  Hamilton Depression Rating Scale score of less than 10

          -  participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL,
             S/VL, L/S or L/VL.

        Exclusion criteria:

          -  Alzheimer's Disease or Mild Cognitive Impairment

          -  any significant medical, psychiatric, and neurological illnesses, e.g., impaired
             liver or kidney function, prior stroke, traumatic brain injury, memory impairment,
             cognitive impairment, parkinsonism, a lifetime history of schizophrenia, bipolar
             disorder, a psychoactive substance use disorder, or current major depression.

          -  known allergy to benzodiazepines

          -  current use (within the previous four weeks) of benzodiazepines or other medications
             known to interact with lorazepam, current use of sedating antihistamines, or current
             use of stimulant medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Stonnington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan A Light, LPN</last_name>
    <phone>(480) 301-8788</phone>
    <email>Light.Jan@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruce Henslin</last_name>
    <phone>480-301-8549</phone>
    <email>henslin.bruce@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 30, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Cynthia M. Stonnington, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease (AD)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
